GlycoMimetics to Receive European Patent for GMI-1271

7/6/17

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the European Patent Office has issued an “intention to grant” letter for European Patent Application Number EP12813711.1, titled “E-Selectin Antagonist Compounds, Compositions, and Methods of Use.” This patent is part of GlycoMimetics’ expanding patent portfolio covering the drug candidate GMI-1271 and its uses in a variety of indications, including various cancers. The U.S. Patent and Trademark Office has already issued a patent covering GMI-1271. GlycoMimetics has ongoing efforts to secure additional U.S. and foreign patents. With the issuance of patents in the U.S. and Europe, GlycoMimetics will have claims directed at GMI-1271 extending at least until 2032.

“The European Patent Office’s issuance of patent rights covering GMI-1271 underscores the progress we’ve made in protecting our intellectual property and innovative pipeline,” said Rachel King, Chief Executive Officer, GlycoMimetics. “The release of promising new clinical data in both the newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) patient populations from our ongoing study during the 2017 ASCO and EHA meetings, the U.S. Food and Drug Administration’s (FDA) Breakthrough Therapy Designation, and our enhanced patent position provide a strong foundation for defining a pivotal registration program and commercialization strategy for GMI-1271.”

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics’ most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial in multiple myeloma. The U.S. FDA recently granted GMI-1271 Breakthrough Therapy designation for treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.

Baltimore Business Spotlight

Feature Your Business Here

Connect with these Baltimore Professionals on LinkedIn

  • Edwin Warfield

    Editor in Chief, Warfield Digital

    Connect
  • Jean Halle

    Independent Consultant

    Connect
  • Larry Lichtenauer

    President of Lawrence Howard & Associates

    Connect
  • Newt Fowler

    Partner at Womble Carlyle, LLP

    Connect
  • David Crowley

    Owner at Develop DC

    Connect
  • Carolyn Stinson

    Stinson Marketing Group

    Connect